ADMA Biologics stock is poised for significant upside potential. With rumors of a potential buyout looming, investors are scrambling to capitalize on this penny stock. Cramer predicts the biotech stock could skyrocket to over $100 billion on FDA approval. Don't miss out on this opportunity! Buy ADMA stock now for huge gains.